Cargando…

Lung Cancer Adverse Events Reports for Angiotensin-Converting Enzyme Inhibitors: Data Mining of the FDA Adverse Event Reporting System Database

Because of contradictory evidence from clinical trials, the association between angiotensin-converting enzyme inhibitors (ACEIs) and lung cancer needs further evaluation. As such, the current study is to assess disproportionate reporting of primary malignant lung cancer among reports for ACEIs submi...

Descripción completa

Detalles Bibliográficos
Autores principales: Meng, Long, Yang, Bing, Qiu, Feng, Jia, Yuntao, Sun, Shusen, Yang, JunQing, Huang, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7882608/
https://www.ncbi.nlm.nih.gov/pubmed/33598469
http://dx.doi.org/10.3389/fmed.2021.594043
_version_ 1783651085356892160
author Meng, Long
Yang, Bing
Qiu, Feng
Jia, Yuntao
Sun, Shusen
Yang, JunQing
Huang, Jing
author_facet Meng, Long
Yang, Bing
Qiu, Feng
Jia, Yuntao
Sun, Shusen
Yang, JunQing
Huang, Jing
author_sort Meng, Long
collection PubMed
description Because of contradictory evidence from clinical trials, the association between angiotensin-converting enzyme inhibitors (ACEIs) and lung cancer needs further evaluation. As such, the current study is to assess disproportionate reporting of primary malignant lung cancer among reports for ACEIs submitted to the FDA adverse event reporting system utilizing a pharmacovigilance approach. We conducted a disproportionality analysis of primary malignant lung cancer adverse events associated with 10 ACEIs by calculating the reported odds ratios (ROR) and information component (IC) with 95% confidence intervals (CI). ROR was adjusted for sex, age, and reporting year by logistic regression analyses. From January 2004 to March 2020, a total of 622 cases of lung cancer adverse event reports were identified for ACEIs users. Significant disproportionate association was found for ACEIs as a drug class (ROR: 1.22, 95% CI: 1.13–1.32; IC: 0.28, 95% CI: 0.17–0.39. adjusted ROR: 1.23, 95% CI: 1.02–1.49). After stratification based on gender, a subset analysis suggested that female patients exhibited a significant disproportionate association, while male patients did not. Sensitivity analyses that limited the data by reporting region, comorbidity, and reporting year also showed similar trends. Statistical significant lung cancer signals were detected among patients who received ACEI, especially female patients. The disproportionality analysis of the FAERS database suggests mildly increased reporting of lung cancer among ACEI users. Further robust epidemiological studies are necessary to confirm this relationship.
format Online
Article
Text
id pubmed-7882608
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-78826082021-02-16 Lung Cancer Adverse Events Reports for Angiotensin-Converting Enzyme Inhibitors: Data Mining of the FDA Adverse Event Reporting System Database Meng, Long Yang, Bing Qiu, Feng Jia, Yuntao Sun, Shusen Yang, JunQing Huang, Jing Front Med (Lausanne) Medicine Because of contradictory evidence from clinical trials, the association between angiotensin-converting enzyme inhibitors (ACEIs) and lung cancer needs further evaluation. As such, the current study is to assess disproportionate reporting of primary malignant lung cancer among reports for ACEIs submitted to the FDA adverse event reporting system utilizing a pharmacovigilance approach. We conducted a disproportionality analysis of primary malignant lung cancer adverse events associated with 10 ACEIs by calculating the reported odds ratios (ROR) and information component (IC) with 95% confidence intervals (CI). ROR was adjusted for sex, age, and reporting year by logistic regression analyses. From January 2004 to March 2020, a total of 622 cases of lung cancer adverse event reports were identified for ACEIs users. Significant disproportionate association was found for ACEIs as a drug class (ROR: 1.22, 95% CI: 1.13–1.32; IC: 0.28, 95% CI: 0.17–0.39. adjusted ROR: 1.23, 95% CI: 1.02–1.49). After stratification based on gender, a subset analysis suggested that female patients exhibited a significant disproportionate association, while male patients did not. Sensitivity analyses that limited the data by reporting region, comorbidity, and reporting year also showed similar trends. Statistical significant lung cancer signals were detected among patients who received ACEI, especially female patients. The disproportionality analysis of the FAERS database suggests mildly increased reporting of lung cancer among ACEI users. Further robust epidemiological studies are necessary to confirm this relationship. Frontiers Media S.A. 2021-02-01 /pmc/articles/PMC7882608/ /pubmed/33598469 http://dx.doi.org/10.3389/fmed.2021.594043 Text en Copyright © 2021 Meng, Yang, Qiu, Jia, Sun, Yang and Huang. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Meng, Long
Yang, Bing
Qiu, Feng
Jia, Yuntao
Sun, Shusen
Yang, JunQing
Huang, Jing
Lung Cancer Adverse Events Reports for Angiotensin-Converting Enzyme Inhibitors: Data Mining of the FDA Adverse Event Reporting System Database
title Lung Cancer Adverse Events Reports for Angiotensin-Converting Enzyme Inhibitors: Data Mining of the FDA Adverse Event Reporting System Database
title_full Lung Cancer Adverse Events Reports for Angiotensin-Converting Enzyme Inhibitors: Data Mining of the FDA Adverse Event Reporting System Database
title_fullStr Lung Cancer Adverse Events Reports for Angiotensin-Converting Enzyme Inhibitors: Data Mining of the FDA Adverse Event Reporting System Database
title_full_unstemmed Lung Cancer Adverse Events Reports for Angiotensin-Converting Enzyme Inhibitors: Data Mining of the FDA Adverse Event Reporting System Database
title_short Lung Cancer Adverse Events Reports for Angiotensin-Converting Enzyme Inhibitors: Data Mining of the FDA Adverse Event Reporting System Database
title_sort lung cancer adverse events reports for angiotensin-converting enzyme inhibitors: data mining of the fda adverse event reporting system database
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7882608/
https://www.ncbi.nlm.nih.gov/pubmed/33598469
http://dx.doi.org/10.3389/fmed.2021.594043
work_keys_str_mv AT menglong lungcanceradverseeventsreportsforangiotensinconvertingenzymeinhibitorsdataminingofthefdaadverseeventreportingsystemdatabase
AT yangbing lungcanceradverseeventsreportsforangiotensinconvertingenzymeinhibitorsdataminingofthefdaadverseeventreportingsystemdatabase
AT qiufeng lungcanceradverseeventsreportsforangiotensinconvertingenzymeinhibitorsdataminingofthefdaadverseeventreportingsystemdatabase
AT jiayuntao lungcanceradverseeventsreportsforangiotensinconvertingenzymeinhibitorsdataminingofthefdaadverseeventreportingsystemdatabase
AT sunshusen lungcanceradverseeventsreportsforangiotensinconvertingenzymeinhibitorsdataminingofthefdaadverseeventreportingsystemdatabase
AT yangjunqing lungcanceradverseeventsreportsforangiotensinconvertingenzymeinhibitorsdataminingofthefdaadverseeventreportingsystemdatabase
AT huangjing lungcanceradverseeventsreportsforangiotensinconvertingenzymeinhibitorsdataminingofthefdaadverseeventreportingsystemdatabase